Научно-практический журнал Медицинские технологии. Оценка и выбор
  • Русский
  • English

Medical Technologies. Assessment and Choice. № 4 | 2019 (38)

DOI: https://doi.org/10.31556/2219-0678.2019.38.4 meta

Full journal issue

 

Article Pages
NEWS DIGEST
5-7
METHODOLOGY
The Assessment of Potential Benefit and Risk Balance in the Process of Clinical Practice Guidelines Development and Grading the Evidence
Kovalyova M.Y., Fedyaeva V.K.
8-17
INTERNATIONAL EXPERIENCE
Comparative Analysis of Nomenclature of Medical Services and International Classification of Health Interventions of the World Health Organization
Tyurina I.V., Avxentyeva M.V.
18-26
MANAGEMENT IN HEALTH CARE
Improving the Access to Radionuclide Therapy for Prostate Cancer within Compulsory Health Insurance System at the Regional Level: Experience of the Kemerovo Region
Lutsenko V.A., Vyalova K.V., Bulbenko P.V., Zheleznyakova I.A.
27-34
Optimization of the Research and Advisory Department of the Oncological Center
Doroshev I.A., Stilidi I.S., Zavolskaia Z.A., Riabchikov D.A., Volkova E.S., Kulushev V.M., Kobiakova E.A., Kazakov A.M., Artemev S.A., Ilin S.N.
35-39
Legal Aspects of Non-Interventional Studies Conduction
Goldina T.A., Suvorov N.I., Remizova A.V., Zhigunova D.S., Moryleva O.N., Krechikov V.A., Murashko I.S.
40-48
ORIGINAL RESEARCH
Telemedicine Technologies in Psychiatry and Narcology: Specialists’ Point of View
Skripov V.S., Semenova N.V., Kochorova L.V., Shvedova A.A., Sazhin V.L., Chekhonadsky I.I.
49-54
Inclusion of Ipragliflozin into the Vital and Essential Drugs List: Budget Impact Analysis
Boyarskaya T.V., Derkach E.V.
55-61
Clinical and Economic Study of Daratumumab in Combination Therapy for Previously Treated Patients with Multiple Myeloma
Avxentyev N.A., Derkach E.V., Makarov A.S.
62-75
Effectiveness and Safety of Targeted Drugs for the Treatment of Adults with Moderate-to-severe Plaque Psoriasis in the Russian Federation
Tolkachyova D.G., Sokolova V.D., Mladov V.V.
76-86
Assessment of Clinical and Economic Effectiveness of Alectinib for Patients with ALK+ Non-Small Cell Lung Cancer without Previous Experience of Targeted Therapy
Nedogoda S.V., Salasyuk A.S., Barykina I.N., Smirnova V.O., Popova E.A.
87-100